DETAILED REPORT: THE DIFFERENCES BETWEEN NAD+ AND NADH

  1. INTRODUCTION

NAD (Nicotinamide Adenine Dinucleotide) is an important coenzyme that exists in two main forms: NAD+ (oxidized form) and NADH (reduced form). They play a central role in cellular energy metabolism, redox balance, DNA repair, inflammation control, and anti-aging.

The differences between NAD+ and NADH are not only in their chemical structure but also clearly reflected in their mechanisms of action, supplementation applications, dosage, and side effects.

This report synthesizes biochemical studies, clinical trials, and systematic reviews to clarify these aspects.

  1. CHEMICAL DIFFERENCES AND MAIN MECHANISMS OF ACTION

NAD+ is the oxidized form (with a positive charge). When it accepts a hydride (H⁻), NAD+ is converted to NADH. The reversible reaction is: NAD⁺ + H⁻ ⇌ NADH. The difference lies only in one hydride containing electrons. 

Main Mechanisms of Action (Significantly Different):

  • NAD+ (electron acceptor – “empty bus”):
  • It acts as an electron acceptor in oxidation reactions, for example in glycolysis (glyceraldehyde-3-phosphate dehydrogenase step) and the Krebs cycle (TCA cycle).
  • It serves as an essential substrate to activate important signaling enzymes, especially sirtuins (SIRT1–SIRT7) – involved in DNA repair, anti-aging, inflammation control, and improvement of mitochondrial function; PARP (poly-ADP-ribose polymerase) – repairs DNA when damage occurs; CD38/CD157 – regulate immunity and metabolism.

Maintaining a high NAD+/NADH ratio in cells supports metabolism directed toward repair, reduction of chronic inflammation, and promotion of longevity (healthy lifespan).

Main role: “Cellular manager” – controls hundreds of signaling processes and indirectly reduces oxidative stress by activating cellular protection pathways.

  • NADH (electron donor – “energy-loaded truck”):
  • As the reduced form, it carries electrons (in the form of hydride) from catabolic reactions to the electron transport chain (ETC) in the mitochondria, creating a proton gradient across the mitochondrial membrane and promoting ATP synthesis through oxidative phosphorylation.
  • It participates directly in cellular energy production, especially in the mitochondria where the NADH/NAD+ ratio is usually higher than in the cytosol.
  • When the NADH level is high, it strongly promotes energy metabolism; however, if in excess (reductive stress), it can lead to electron leakage from the ETC, increasing the production of ROS (reactive oxygen species) and causing oxidative stress.
  • NADH is not a substrate for sirtuins (sirtuins have very low affinity for NADH, about 1000 times lower than for NAD+), so it has little involvement in anti-aging signaling pathways and DNA repair.

Main role: “Energy transporter” – focuses on supplying electrons for ATP production and has little involvement in longevity signaling processes compared to NAD+.

The NAD+/NADH ratio in healthy cells is very high in the cytosol (approximately 60–700:1 depending on the tissue), reflecting the oxidized state necessary for catabolic reactions. In contrast, in the mitochondria, the NADH/NAD+ ratio is higher to support ATP production. Imbalance (decrease in NAD+ with age) leads to a reduced NAD+/NADH ratio, which is associated with aging, type 2 diabetes, neurodegenerative diseases, and mitochondrial dysfunction.

  1. THE ROLE OF NAD+ IN CELLULAR MANAGEMENT PROCESSES

NAD+ is not only a coenzyme participating in redox reactions (electron exchange) but also a substrate (consumed substrate) for many important enzymes. When NAD+ is used by these enzymes, it is broken down into nicotinamide (NAM) and ADP-ribose (or their derivatives).

The main enzymes that consume NAD+ include:

  • Sirtuins (SIRT1–SIRT7)
  • PARPs (especially PARP1)
  • CD38/CD157 (NAD+ glycohydrolases / NADases)

The balance between NAD+ production and consumption determines the activation level of repair, anti-aging, and inflammation control pathways. When NAD+ decreases (commonly seen with aging), these functions are weakened.

  • DNA Repair (DNA repair)

NAD+ participates in DNA repair mainly through two pathways:

Through PARP (Poly-ADP-ribose polymerase, especially PARP1):

  • When there is DNA damage (DNA strand breaks due to oxidative stress, UV rays, chemicals…), PARP1 quickly binds to the damaged site and uses NAD+ as a substrate to attach poly-ADP-ribose (PAR) chains to itself and other proteins.
  • This action creates signals to recruit other DNA repair proteins (such as XRCC1, DNA ligase III…).
  • If DNA damage accumulates a lot (as in aging or progeria), PARP is chronically activated → consumes a very large amount of NAD+ → leads to NAD+ depletion, reduced sirtuin activity, and causes cellular energy disorders.
  • Supplementing NAD+ precursors (NR/NMN) or inhibiting PARP can help restore this balance.
  • Through Sirtuins:
  • SIRT1 and SIRT6 participate in DNA repair by deacetylating histones and repair proteins (such as p53, Ku70, PARP1 itself). They help maintain genome stability and telomeres.
  • SIRT6 is particularly important in repairing DNA double-strand breaks and maintaining telomeres.
  • Anti-aging (Anti-aging / Longevity)
  • NAD+ is a key factor for sirtuins – known as “anti-aging enzymes”.
  • Sirtuins use NAD+ to remove acetyl groups from histones and non-histone proteins (deacetylation), thereby regulating gene expression, enhancing DNA repair, improving metabolism, and increasing stress resistance.
  • SIRT1: Regulates p53, NF-κB, FOXO, PGC-1α → promotes DNA repair, reduces inflammation, increases mitochondrial biogenesis.
  • SIRT3: In mitochondria, deacetylates enzymes of the Krebs cycle, β-oxidation, and antioxidant enzymes (SOD2) → improves mitochondrial function.
  • When NAD+ decreases with age (40–70% in many tissues), sirtuin activity declines → accumulation of DNA damage, mitochondrial dysfunction, chronic inflammation, and signs of aging (hallmarks of aging).
  • Supplementing NAD+ helps restore sirtuin activity, mimicking the effects of caloric restriction – a method proven to extend lifespan in many species.
  • Inflammation Control (Inflammation control)
  • Through Sirtuins: SIRT1 deacetylates NF-κB (the main transcription factor causing inflammation) → inhibits the expression of inflammatory genes (cytokines such as TNF-α, IL-6).
  • Through PARP: PARP1 can also promote inflammation when strongly activated, but NAD+ helps balance between repair and inflammation.
  • Through CD38: CD38 is the strongest NAD+-consuming enzyme in “inflammaging” (chronic inflammation with age). When inflammation increases (due to LPS, SASP from senescent cells…), CD38 expression increases strongly (can increase hundreds of times in M1 macrophages), leading to NAD+ depletion → worsening inflammation and mitochondrial dysfunction. Inhibiting CD38 helps increase NAD+, reduce inflammation, and improve immune function.
  • Improvement of Mitochondrial Function (Mitochondrial function)
  • Through SIRT3 (mitochondria): Deacetylates and activates important enzymes in the Krebs cycle, electron transport chain (ETC), fatty acid β-oxidation, and anti-ROS (SOD2, IDH2…).
  • NAD+ helps maintain an appropriate NAD+/NADH ratio to support efficient ATP production and reduce electron leakage causing ROS.
  • When NAD+ is low → mitochondrial dysfunction → decreased ATP, increased ROS, decreased mitophagy (autophagy of mitochondria) → contributing to aging and metabolic diseases.
  • Supplementing NAD+ or inhibiting CD38 has been proven to improve mitochondrial respiration and increase mitochondrial biogenesis (through PGC-1α activated by SIRT1).
  • Role of CD38/CD157 – Regulation of Immunity and Metabolism
  • CD38 and CD157 are NAD+ glycohydrolases (NADases) mainly located on the surface of immune cells.
  • They break down NAD+ into cyclic ADP-ribose (cADPR) – an important calcium signaling molecule in the activation of T cells, B cells, macrophages, and immune responses.
  • In aging and chronic inflammation, CD38 increases strongly → large consumption of NAD+ → reduces available NAD+ for sirtuins and PARP → vicious cycle: increased inflammation → decreased NAD+ → poor mitochondria → more severe inflammation.
  • CD38 also affects glucose and lipid metabolism. Inhibiting CD38 (by drugs or knockout) in aged mice helps increase NAD+, improve mitochondrial function, glucose tolerance, and muscle function.

 

Summary of the Competitive Relationship

NAD+ is a “resource” contested between:

  • Sirtuins (good for longevity, repair, anti-inflammation)
  • PARP (urgent for emergency DNA repair)
  • CD38 (related to immunity and inflammation)

As age increases or under chronic stress, PARP and CD38 “consume” more NAD+ → sirtuins lack “fuel” → accelerating aging. Therefore, strategies to increase NAD+ (NR, NMN, IV NAD+, CD38 inhibition) aim to restore this balance.

4.HOW NADH PRODUCES ENERGY FOR ATP

NADH does not directly create ATP but transfers electrons to the electron transport chain (ETC) in the inner mitochondrial membrane – this is the most important step in oxidative phosphorylation.

Detailed mechanism: NADH binds to Complex I (NADH dehydrogenase). NADH is oxidized: NADH → NAD⁺ + H⁺ + 2e⁻. The two electrons are transferred through FMN, iron-sulfur clusters to ubiquinone (CoQ). At the same time, Complex I pumps 4 protons (H⁺) from the mitochondrial matrix out to the intermembrane space.

Electrons continue to move: Ubiquinone carries electrons to Complex III (pumps an additional 4 protons), then through cytochrome c to Complex IV (pumps an additional 2 protons and combines with oxygen to create water: ½ O₂ + 2H⁺ + 2e⁻ → H₂O). In total, from 1 NADH, approximately 10 protons are pumped out to the intermembrane space, creating a proton gradient (proton motive force).

The proton gradient is used through Complex V (ATP synthase): Protons flow back into the matrix, turning the rotor of ATP synthase and catalyzing the reaction ADP + Pi → ATP.

Amount of ATP from 1 NADH: According to modern data, approximately 2.5 ATP (some older sources round it to 3 ATP). General reaction summary: NADH + H⁺ + ½ O₂ + ADP + Pi → NAD⁺ + H₂O + ATP (approximately 2.5 molecules).

Important note: NADH is the “energy-loaded truck” that directly supplies electrons to the ETC. However, if NADH is in excess causing reductive stress, it may increase ROS production and reduce ATP efficiency. This is why a high NAD+/NADH ratio is often good for long-term health, while NADH focuses on short-term energy.

5.SUPPLEMENTATION APPLICATIONS AND CLINICAL RESEARCH

NADH is mainly supplemented orally with low doses (usually 5–10 mg/day). The oral form has been studied in many clinical trials for conditions such as chronic fatigue syndrome (CFS), Alzheimer’s disease, and Parkinson’s disease, showing improvements in quality of life, reduced fatigue, and some cognitive indicators.

There are some older studies (mainly from the 1990s) using NADH intravenous (IV) or intramuscular injection at a dose of about 25 mg/day for 10–14 days in Parkinson’s disease, reporting some improvement in motor symptoms.

In contrast, NAD+ is poorly absorbed when taken orally (rapidly broken down in the digestive tract), so it is usually supplemented in the form of precursors such as NR (nicotinamide riboside) or NMN (nicotinamide mononucleotide) orally, or in the form of intravenous (IV) infusion to rapidly increase endogenous NAD+ levels. NAD+ IV is more commonly used in clinics at doses of 500–1,500 mg/session, providing rapid effects but requiring slow infusion to reduce side effects.

Overall clinical studies show that both forms are safe at recommended doses, but their mechanisms and applications differ markedly: NADH focuses on direct energy production support, while NAD+ (via precursors or IV) focuses on raising total NAD+ levels to activate sirtuins and repair pathways. More than 70 studies on NR/NMN show significant increases in blood NAD+ levels, improved insulin sensitivity, muscle function, and reduced inflammation in the elderly, obese individuals, prediabetes, and Parkinson’s disease.

6.SIDE EFFECTS

  • NADH oral: Very safe at low doses. Mild and infrequent side effects: muscle pain, neurological disorders, fatigue, sleep disturbances, headache. No serious reports.
  • NADH IV: Very safe at the suggested low dose of 250mg per week. Mild and infrequent side effects: muscle pain, neurological disorders, fatigue, sleep disturbances, headache. However, there are fewer studies compared to NAD+ IV.
  • NR/NMN (NAD+ precursors): Highly safe at 250–2,000 mg/day. Mild side effects: nausea, bloating, skin itching, headache, diarrhea. Rarely increased cholesterol at very high doses.
  • NAD+ IV: Well tolerated if infused slowly. Common side effects when infused quickly: nausea, facial flushing, dizziness, chest tightness, rapid heartbeat, headache. These are markedly reduced when infused slowly over 2–6 hours with good hydration. No serious liver or kidney toxicity at recommended doses.

Overall, NAD supplementation has a high safety profile with few or no serious side effects in clinical trials.

7.RECOMMENDED DOSAGE COMPARISON

  • NADH form: Typical dosage is 5–10 mg per day, which can be increased to 10–15 mg (even up to 25 mg) in pathological conditions. Route of administration is oral and IV. Duration of use is usually from 12 weeks to 24 months. Note: Commonly applied for chronic fatigue syndrome (CFS), Alzheimer’s disease, and Parkinson’s disease. Stabilized NADH (such as ENADA) has been used in clinical trials.
  • NR/NMN form (NAD+ precursors): Typical dosage is 250–2,000 mg per day (most commonly 300–1,000 mg). Some studies have tested safety up to 3 g NR per day. Route of administration is oral. Duration of use is usually from 4–26 weeks, with some trials longer (up to 48 weeks). Note: Used to increase whole-body NAD+ levels. NR and NMN show comparable results in raising blood NAD+ levels.
  • NAD+ IV form (intravenous injection): Typical dosage is 500–1,500 mg per session. Route of administration is intravenous. Usage schedule is usually a loading phase of 4 consecutive days, followed by maintenance of 1–2 times per week depending on the purpose. Note: Commonly used for severe fatigue or addiction support. Should be infused slowly over 2–6 hours with good hydration to reduce side effects.

General notes: Direct oral NAD+ is not recommended due to very low bioavailability. NADH is used at very low doses and focuses on direct energy production support. NR/NMN helps the body synthesize endogenous NAD+ internally, so the dose is much higher. IV NAD+ provides fast and strong effects but requires medical supervision. Actual dosage should be adjusted according to individual health conditions and always consult a physician.

CONCLUSION AND RECOMMENDATIONS

NAD+ and NADH are the same molecule but in two different redox states: NAD+ focuses on signaling, sirtuin activation, and repair; NADH focuses on ATP production. NADH supplementation at low oral doses is suitable for energy and chronic diseases; NAD+ is usually given via NR/NMN or IV to increase total endogenous NAD+ levels and strongly activate sirtuins.

Both have evidence from dozens of clinical trials showing benefits on energy, inflammation, metabolism, and aging, with a good safety profile. However, clinical efficacy on anti-aging is not yet fully convincing and requires more long-term studies.

Practical recommendations: Combine supplementation with a healthy lifestyle (exercise, intermittent fasting, diet rich in vitamin B3) to naturally maintain the NAD+/NADH ratio.

Consult a physician before use, especially if there are underlying medical conditions or taking other medications.

The information in this report is for scientific reference only and does not replace professional medical advice.

For all product details, please contact,

JN Beauty Solutions®

Beauty From Science